Abstract:Since the discovery of rapamycin, considerable progress has been made in unraveling the details of the mammalian target of rapamycin (mTOR) signaling network, including the upstream mechanisms that modulate mTOR signaling functions, and the roles of mTOR in the regulation of mRNA translation and other cell growth-related responses. mTOR is found in two different complexes within the cell, mTORC1 and mTORC2, but only mTORC1 is sensitive to inhibition by rapamycin. mTORC1 is a master controller of protein synthesis, integrating signals from growth factors within the context of the energy and nutritional conditions of the cell. Activated mTORC1 regulates protein synthesis by directly phosphorylating 4E-binding protein 1 (4E-BP1) and p70S6K (S6K), translation initiation factors that are important to cap-dependent mRNA translation, which increases the level of many proteins that are needed for cell cycle progression, proliferation, angiogenesis, and survival pathways. In normal physiology, the roles of mTOR in both glucose and lipid catabolism underscore the importance of the mTOR pathway in the production of metabolic energy in quantities sufficient to fuel cell growth and mitotic cell division. Several oncogenes and tumor-suppressor genes that activate mTORC1, often through the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, are frequently dysregulated in cancer. Novel analogs of rapamycin (temsirolimus, everolimus, and deforolimus), which have improved pharmaceutical properties, were designed for oncology indications. Clinical trials of these analogs have already validated the importance of mTOR inhibition as a novel treatment strategy for several malignancies. Inhibition of mTOR now represents an attractive anti-tumor target, either alone or in combination with strategies to target other pathways that may overcome resistance. The far-reaching downstream consequences of mTOR inhibition make defining the critical molecular effector mechanisms that mediate the anti-tumor response and associated biomarkers that predict responsiveness to mTOR inhibitors a challenge and priority for the field.

Lipid sensing by mTOR complexes via de novo synthesis of phosphatidic acid

Mtorc1 Phosphorylates Acetyltransferase P300 to Regulate Autophagy and Lipogenesis.

Amino Acid Regulation of TOR Complex 1.

Malonyl-CoA is a conserved endogenous ATP-competitive mTORC1 inhibitor

Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP

mTOR complex-2 stimulates acetyl-CoA and de novo lipogenesis through ATP citrate lyase in HER2/PIK3CA-hyperactive breast cancer.

Recent Advances in Understanding Amino Acid Sensing Mechanisms that Regulate mTORC1

mTORC2-AKT signaling to ATP-citrate lyase drives brown adipogenesis and de novo lipogenesis

Sensors for the Mtorc1 Pathway Regulated by Amino Acids

Advances in the Mechanisms of Amino Acid Signaling in mTORC1 Pathway

Growth Factor Signaling to Mtorc1 by Amino Acid-Laden Macropinosomes

Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.

Tyrosine phosphorylation of DEPTOR functions as a molecular switch to activate mTOR signaling

PtdIns3P controls mTORC1 signaling through lysosomal positioning.

Integrated proteasomal and lysosomal activity shape mTOR-regulated proteome remodeling

mTORC1 activity repression by late endosomal phosphatidylinositol 3,4-bisphosphate

mTORC1 controls murine postprandial hepatic glycogen synthesis via Ppp1r3b

Structural basis for growth factor and nutrient signal integration on the lysosomal membrane by mTORC1

Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids

Mtor Modulates Cellular Fat Metabolism by Regulating Stearoyl-Coa Desaturase 1 Transcription.

Inhibition of mitochondrial fatty acid β-oxidation activates mTORC1 pathway and protein synthesis via Gcn5-dependent acetylation of Raptor in zebrafish